



Guerbet commits to supporting women's health with its launch of a specialized website

Villepinte (France), May 6, 2019 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has announced the creation of a specialized website for healthcare professionals dedicated to women's health and in particular to issues relating to the diagnosis and treatment of infertility and breast cancer: www.guerbet-womenhealthcare.com.

Infertility and breast cancer are two major concerns worldwide. Guerbet's objective is to improve the quality of diagnosis, so that health professionals can offer patients more appropriate personalized treatment and thus improve treatment outcomes.

"Guerbet is a newcomer in the field of women's health. Our activities are underpinned by the use of our solutions in the diagnosis of infertility and detection of the sentinel node in breast cancer," said **Thomas Bonnefont, VP Commercial Interventional Imaging for Guerbet**. *"We are delighted to be able to offer professionals easier access to quality scientific information on these conditions. With this new website, we are demonstrating our commitment to work at their side as of today with the aim of truly improving diagnosis and patient treatment."*

This new site will group epidemiological data (prevalence, causes, etc.), information on available treatments and diagnoses, an agenda of scientific conferences and clinical data, as well as information on some of the solutions proposed by Guerbet with their modes of action.

Infertility is defined as a couple's inability to conceive after more than 12 months of unprotected intercourse. Some cases of infertility are associated with female conditions, including fallopian tube or uterine cavity abnormalities, endometriosis or ovulation problems; female infertility affects more than 10% of women¹. Infertility can also be caused by male conditions (sperm quality, etc.), or a combination of both. But it is a complex disorder, and in 15–30% of cases its causes remain unknown².

Breast cancer, meanwhile, is the second most common cancer in the world and the most common cancer among women. It is also the fifth leading cause of cancer death worldwide¹.

Guerbet is stepping up its developments in this field with the aim of meeting medical needs associated with these two conditions as part of its interventional imaging business. Guerbet has also created a second website dedicated to interventional radiologists, providing professionals with rich scientific content on mini-invasive procedures and the associated diseases: www.guerbet-interventional.com.

¹ World Health Organization - Sexual and Reproductive Health - <https://www.who.int/reproductivehealth/topics/infertility/perspective/en/>.

² Gelbaya TA et al. Definition and epidemiology of unexplained infertility. *Obstet Gynecol Surv.* 2014 Feb;69(2):109-15.

Press release

About Guerbet

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com

Media Relations

Guerbet Global

Alize RP

Caroline Carmagnol / Tatiana Vieira

+33 (0)1 44 54 36 66 / +33 (0)6 31 13 76 20

guerbet@alizerp.com

ⁱ GLOBOCAN, Cancer Fact Sheets: Breast cancer, 2012, <http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp>.